Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer’s Disease

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|22|14|2064-2071

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.22, Iss.14, 2016-04, pp. : 2064-2071

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Muscarinic Receptor Agonists and Antagonists in the Treatment of Alzheimer's Disease

By  

Current Pharmaceutical Design, Vol. 11, Iss. 26, 2005-10 ,pp. : 3353-3361

Bentham Science Publishers

Access to resources Recommend Favorite

Serotonergic drugs and valvular heart disease

By Rothman Richard B   Baumann Michael H  

Expert Opinion on Drug Safety, Vol. 8, Iss. 3, 2009-05 ,pp. : 317-329

Informa Healthcare

Access to resources Recommend Favorite

Muscarinic M1 agonists in the treatment of Alzheimer’s disease

By Korczyn A.D.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 10, 2000-10 ,pp. : 2259-2267

Informa Healthcare

Access to resources Recommend Favorite

Muscarinic M1 receptor agonists and M2 receptor antagonists as therapeutic targets in Alzheimer’s disease

By Sheardown Malcolm J  

Expert Opinion on Therapeutic Patents, Vol. 12, Iss. 6, 2002-06 ,pp. : 863-870

Informa Healthcare

Access to resources Recommend Favorite

Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease

By Martinez Ana   Castro Ana  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 1, 2006-01 ,pp. : 1-12

Informa Healthcare

Access to resources Recommend Favorite